EA201992540A1 - Способы количественного определения интер-альфа ингибиторных белков - Google Patents

Способы количественного определения интер-альфа ингибиторных белков

Info

Publication number
EA201992540A1
EA201992540A1 EA201992540A EA201992540A EA201992540A1 EA 201992540 A1 EA201992540 A1 EA 201992540A1 EA 201992540 A EA201992540 A EA 201992540A EA 201992540 A EA201992540 A EA 201992540A EA 201992540 A1 EA201992540 A1 EA 201992540A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
inter
iaip
quantitative determination
alpha inhibitor
Prior art date
Application number
EA201992540A
Other languages
English (en)
Inventor
Йоу-Пин Лим
Денис Сперо
Original Assignee
Протера Байолоджикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Протера Байолоджикс, Инк. filed Critical Протера Байолоджикс, Инк.
Priority claimed from PCT/US2018/029436 external-priority patent/WO2018200722A1/en
Publication of EA201992540A1 publication Critical patent/EA201992540A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

В изобретении описаны способы количественного определения уровней IAIP в образце (например, полученном у субъекта) с использованием анализов на основе лиганда IAIP. Также раскрыты способы измерения комплексов IAIP-лиганд IAIP и способы оценки, контроля и лечения субъектов с использованием вышеупомянутых способов количественного определения IAIP.
EA201992540A 2018-01-05 2018-04-25 Способы количественного определения интер-альфа ингибиторных белков EA201992540A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862614333P 2018-01-05 2018-01-05
PCT/US2018/029436 WO2018200722A1 (en) 2017-04-25 2018-04-25 Methods for quantifying inter-alpha inhibitor proteins

Publications (1)

Publication Number Publication Date
EA201992540A1 true EA201992540A1 (ru) 2020-08-05

Family

ID=72235054

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992540A EA201992540A1 (ru) 2018-01-05 2018-04-25 Способы количественного определения интер-альфа ингибиторных белков

Country Status (1)

Country Link
EA (1) EA201992540A1 (ru)

Similar Documents

Publication Publication Date Title
EA201991461A1 (ru) Способы и устройства для оценки содержания материалов
WO2017070114A3 (en) Diabetes-related biomarkers and treatment of diabetes-related conditions
MX2019007653A (es) Métodos para la optimización de ensayos rápidos de susceptibilidad antimicrobiana.
DE60315715D1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
CA2701341A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
ATE430936T1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
BR112022011676A2 (pt) Kit para detectar um analito de interesse em uma pluralidade de amostras líquidas biológicas, método para detectá-lo e /ou quantificá-lo e cartucho para realizar tal método
EA201991506A1 (ru) Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов
CY1119797T1 (el) Λακτοφερινη για χρηση στη διαγνωση και προγνωση της νοσου alzheimer
TR201900481T4 (tr) Bağışıklık testi için aparat ve kit.
MX2019008911A (es) Metodos, matrices y usos de estos.
WO2019066572A3 (en) Method and device for analyzing target analyte in sample
EA202092641A1 (ru) Система и способ анализа поверхности, которая подвержена износу
MY193895A (en) Combination test for colorectal cancer
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
EA201891636A1 (ru) Диагностическое устройство и способ диагностики
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
DE602007006671D1 (de) Verwendung von nnmt als marker für lungenkrebs
WO2016198833A3 (en) Methods for analysing a urine sample
BR112022011674A2 (pt) Biblioteca de micropartículas pré-fabricadas e suas precursoras
EA201992540A1 (ru) Способы количественного определения интер-альфа ингибиторных белков
GB2554282A (en) Lock mass library for internal correction
MX2019000591A (es) Tira mejorada de ensayo de analisis de orina de bajo volumen de muestra, kits analiticos y metodos de uso relacionados con la misma.
TR201814812A2 (tr) Performans ölçme prosesi̇